Cannasat Therapeutics Inc.

Presenter: Anthony Giovinazzo, President & CEO

Company Information

Company Type: Pharmaceuticals

Development Stage: Public

Company Profile

Cannasat is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cannasat has a lower risk Parkinson's drug candidate, which is a reformulation of an approved drug that can address a moderate to severe patient population. In addition, Cannasat has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea/vomiting and appetite stimulation.

Presenter Bio

Mr. Giovinazzo has a total of 31 years of international business experience, of which the last 16 years have been in the CNS field. His experience ranges from the investment side as the former President of the Neuroscience Partners Fund, a limited partnership investing in CNS companies primarily in the US and Canada, and subsequently, as the CEO of several companies. He has extensive experience in licensing drug candidates both in-bound and out-bound, as well as mergers and acquisitions, the management of clinical development, and building international execution focused clinical development teams.
Mr. Giovinazzo is one of the few CEOs in the industry that holds the Chartered Directors designation, which is granted jointly by the Conference Board of Canada and the DeGroote School of Business at McMaster University. He has also completed the Leadership and Strategy in Pharmaceuticals and Biotech, program, at the Harvard Business School.

Contact

Cannasat Therapeutics Inc.
828 Richmond St. West
Toronto
ON, Canada
M6J 1C9

ph: 416-703-2449
fx: 416-703-8752

www.cannasat.com
ajg@cannasat.com